Checkpoint Therapeutics, Inc. – NASDAQ:CKPT
Checkpoint Therapeutics stock price today
$4.26
+0.75
+21.71%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Checkpoint Therapeutics stock price monthly change
+48.94%
month
Checkpoint Therapeutics stock price quarterly change
+48.94%
quarter
Checkpoint Therapeutics stock price yearly change
+60.55%
year
Checkpoint Therapeutics key metrics
Market Cap | 162.73M |
Enterprise value | N/A |
P/E | -3.98 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 166.97 |
Price/Book | -1.01 |
PEG ratio | -0.13 |
EPS | -2.37 |
Revenue | N/A |
EBITDA | -44.65M |
Income | -52.31M |
Revenue Q/Q | -100% |
Revenue Y/Y | -61.14% |
Profit margin | -79333.9% |
Oper. margin | -75727.12% |
Gross margin | 15.25% |
EBIT margin | -75727.12% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCheckpoint Therapeutics stock price history
Checkpoint Therapeutics stock forecast
Checkpoint Therapeutics financial statements
| Jun 2023 | 31K | -16.52M | -53293.55% |
|---|---|---|---|
| Sep 2023 | 31K | -5.72M | -18464.52% |
| Dec 2023 | 6K | -19.12M | -318800% |
| Mar 2024 | 0 | -10.94M |
| Dec 2023 | 6K | -19.12M | -318800% |
|---|---|---|---|
| Mar 2024 | 0 | -10.94M | |
| Oct 2025 | 22.03M | 1.64M | 7.47% |
| Dec 2025 | 31.46M | 3.62M | 11.51% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 8338000 | 31.60M | 379.08% |
|---|---|---|---|
| Sep 2023 | 2218000 | 21.26M | 958.57% |
| Dec 2023 | 5378000 | 18.42M | 342.6% |
| Mar 2024 | 11975000 | 22.22M | 185.59% |
| Jun 2023 | -11.97M | 0 | 14.55M |
|---|---|---|---|
| Sep 2023 | -14.75M | 0 | 9.10M |
| Dec 2023 | -6.83M | 0 | 9.98M |
| Mar 2024 | -6.47M | 0 | 12.78M |
Checkpoint Therapeutics alternative data
| Aug 2023 | 24 |
|---|---|
| Sep 2023 | 24 |
| Oct 2023 | 24 |
| Nov 2023 | 24 |
| Dec 2023 | 24 |
| Jan 2024 | 24 |
| Feb 2024 | 24 |
| Mar 2024 | 23 |
| Apr 2024 | 23 |
| May 2024 | 23 |
| Jun 2024 | 23 |
| Jul 2024 | 23 |
Checkpoint Therapeutics other data
5.62%
-15.88%
of CKPT is owned by hedge funds
17
-21
496.35K
-1.40M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 23944 |
| Jun 2024 | 0 | 37648 |
| Dec 2024 | 0 | 1090829 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | OLIVIERO JAMES F III director, officer.. | COMMON STOCK | 220,230 | $3.38 | $744,377 | ||
Sale | OLIVIERO JAMES F III director, officer.. | COMMON STOCK | 602,167 | $3.87 | $2,330,386 | ||
Sale | GRAY WILLIAM GARRETT officer: Chief Fi.. | COMMON STOCK | 268,432 | $4.01 | $1,076,412 | ||
Sale | OLIVIERO JAMES F III director, officer.. | COMMON STOCK | 24,610 | $2.05 | $50,450 | ||
Sale | GRAY WILLIAM GARRETT officer: Chief Fi.. | Common Stock | 13,038 | $2.06 | $26,858 | ||
Sale | OLIVIERO JAMES F III director, officer.. | COMMON STOCK | 5,894 | $2.06 | $12,142 | ||
Sale | GRAY WILLIAM GARRETT officer: Chief Fi.. | Common Stock | 2,035 | $2.07 | $4,212 | ||
Sale | GRAY WILLIAM GARRETT officer: Chief Fi.. | Common Stock | 4,115 | $1.95 | $8,024 | ||
Sale | OLIVIERO JAMES F III director, officer.. | COMMON STOCK | 11,900 | $2.01 | $23,919 | ||
Sale | GRAY WILLIAM GARRETT officer: Chief Fi.. | Common Stock | 3,591 | $5 | $17,955 |
| Patent |
|---|
Application Filling date: 13 Mar 2020 Issue date: 3 Sep 2020 |
Checkpoint: PDUFA Date Catalyst Makes This A Must Watch
Checkpoint Therapeutics: Cosibelimab Data Bolsters Case For Dual-Approval In cSCC
Checkpoint Therapeutics: An Updated Analysis
Checkpoint: Strong Data, But Comes With Risks
Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions
Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results
Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout
Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential
Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data
-
What's the price of Checkpoint Therapeutics stock today?
One share of Checkpoint Therapeutics stock can currently be purchased for approximately $4.26.
-
When is Checkpoint Therapeutics's next earnings date?
Unfortunately, Checkpoint Therapeutics's (CKPT) next earnings date is currently unknown.
-
Does Checkpoint Therapeutics pay dividends?
No, Checkpoint Therapeutics does not pay dividends.
-
How much money does Checkpoint Therapeutics make?
Checkpoint Therapeutics has a market capitalization of 162.73M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 46.35% to 103K US dollars.
-
What is Checkpoint Therapeutics's stock symbol?
Checkpoint Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "CKPT".
-
What is Checkpoint Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Checkpoint Therapeutics?
Shares of Checkpoint Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Checkpoint Therapeutics's key executives?
Checkpoint Therapeutics's management team includes the following people:
- Mr. James F. Oliviero III, C.F.A., CFA Chief Executive Officer, Pres & Director(age: 49, pay: $834,300)
- Mr. William Garrett Gray Chief Financial Officer, Corporation Sec. & Treasurer(age: 38, pay: $296,000)
-
How many employees does Checkpoint Therapeutics have?
As Jul 2024, Checkpoint Therapeutics employs 23 workers.
-
When Checkpoint Therapeutics went public?
Checkpoint Therapeutics, Inc. is publicly traded company for more then 8 years since IPO on 19 Dec 2016.
-
What is Checkpoint Therapeutics's official website?
The official website for Checkpoint Therapeutics is checkpointtx.com.
-
Where are Checkpoint Therapeutics's headquarters?
Checkpoint Therapeutics is headquartered at 95 Sawyer Road, Waltham, MA.
-
How can i contact Checkpoint Therapeutics?
Checkpoint Therapeutics's mailing address is 95 Sawyer Road, Waltham, MA and company can be reached via phone at +7 816524500.
Checkpoint Therapeutics company profile:
Checkpoint Therapeutics, Inc.
checkpointtx.comExchange:
NASDAQ
Full time employees:
23
Industry:
Biotechnology
Sector:
Healthcare
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
95 Sawyer Road
Waltham, MA 02453
Waltham, MA 02453
CIK: 0001651407
ISIN: US1628282063
CUSIP: 162828107
